How much funding has Eiger Biopharmaceuticals raised?

Eiger Biopharmaceuticals has raised $7.1M in total funding, most recently a Series A round.

Who are Eiger Biopharmaceuticals's investors?

Eiger Biopharmaceuticals's investors include InterWest Partners, Vivo Capital.

When was Eiger Biopharmaceuticals founded?

Eiger Biopharmaceuticals was founded in 2008.

Where is Eiger Biopharmaceuticals headquartered?

Eiger Biopharmaceuticals is headquartered in Palo Alto, California, United States.

What industry is Eiger Biopharmaceuticals in?

Eiger Biopharmaceuticals operates in Biotech, Healthcare.

How many employees does Eiger Biopharmaceuticals have?

Eiger Biopharmaceuticals has 11-50 employees.

Eiger Biopharmaceuticals

IPO

Palo Alto, United States · Founded 2008 · $7.1M raised

Biotech

Healthcare

Headquarters: Palo Alto, California
Employees: 11–50
Founded: 2008
Business Model: B2B

Website: eigerbio.com
Total Funding: $7.1M
Last Round: $7.1M Series AAug 2012
Rounds: 1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 3 funding rounds and 2 investors for this company. The full record is or through the API.

About

Eiger BioPharmaceuticals (formerly Celladon Corp) was a commercial-stage biopharmaceutical company founded in 2008 and headquartered in Palo Alto, California, focused on developing and commercializing targeted therapies for serious rare and ultra-rare diseases. The company achieved FDA approval of Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and pursued treatments for Hepatitis Delta (HDV) and other orphan diseases. Following a series of clinical setbacks, Eiger filed for bankruptcy in 2024 and wound down operations.

Summary

Eiger Biopharmaceuticals is a Biotech company based in Palo Alto, United States, founded in 2008. It has raised $7.1M in total across 1 round, most recently a $7.1M Series A round in Aug 2012. Investors include InterWest Partners and Vivo Capital.

Funding & Exit History

Debt FinancingDebt FinancingJun 2022

$75.0M

Jun 2022

Sign up to see all 3 events

Funding: Series A. Amounts, valuations, and investors where available.

Investors

InterWest Partners

Lead

1 round

Vivo Capital

Lead

1 round

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare

Growth EquityTotal funding$5.1BAug 2022

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare

Private EquityTotal funding$3.9BJan 2019

Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare

Private EquityTotal funding$3.0BJan 2004

Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech

Series ATotal funding$3.0BJan 2022

Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare

Private EquityTotal funding$3.0BMay 2017

BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology

Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

<a href="https://indexed.vc/companies/eiger-biopharmaceuticals"><img src="https://indexed.vc/api/badge/company/eiger-biopharmaceuticals" alt="Eiger Biopharmaceuticals on Indexed.vc" width="260" height="76" /></a>